Pouypoudat C, et al. - In this monocentric study involving 79 patients, researchers evaluated tolerance, resection rate and outcomes of patients with non-metastatic pancreatic ductal adenocarcinoma treated by concomitant chemoradiotherapy. The study sample consisted of all consecutive patients treated from 2010 to 2014 for non-metastatic pancreatic adenocarcinoma. Chemotherapy (FOLFIRINOX) was used to treat all patients, followed by chemoradiotherapy for 94% of patients. Data reported that median overall survival was 21.5 months. According to findings, neoadjuvant treatment consisting of FOLFIRINOX chemotherapy followed by chemoradiotherapy is an effective strategy for borderline and locally advanced pancreatic cancer patients, resulting in a 43% rate of secondary complete surgical resection linked to high local control, overall and disease-free survival.